• Home
  • Search Results
  • Captopril and angiotensin II receptor antagonist therapy in a pacing model of heart failure.

Captopril and angiotensin II receptor antagonist therapy in a pacing model of heart failure.

The Canadian journal of cardiology (1998-09-17)
R I Ogilvie, D Zborowska-Sluis

Twenty-four splenectomized dogs were subjected to rapid right ventricular pacing (RRVP) at 250 beats/min for five weeks. During the final three weeks, four groups six dogs were untreated or treated with captopril alone, with the angiotensin II type 1 (AT1) receptor antagonist L158,809 alone or with the two drugs combined by constant intravenous infusion. Hemodynamic studies were carried out during light anesthesia at baseline, and after two and five weeks of pacing. Total vascular capacitance and stressed blood volume were calculated from the mean circulatory filling pressure during transient circulatory arrest after acetylcholine administration at three different circulating volumes. Central blood volume and cardiac output were measured by thermodilution. Severe heart failure was present in the untreated group after five weeks of RRVP, characterized by low cardiac output and total vascular capacitance, high right atrial and pulmonary capillary wedge and mean circulatory filling pressure, plus increased stressed and central blood volumes. While L158,809 had not effect, captopril alone or combined with L158,809 ameliorated the reduction in total vascular capacitance, and reduced right atrial and mean circulatory pressure and stressed blood volumes. Combined therapy reduced pulmonary capillary wedge pressure. Thus, angiotensin-converting enzyme inhibition with captopril was effective in this model of chronic low output heart failure, whereas AT1 receptor antagonism was not.

Product Number
Product Description

Captopril, meets USP testing specifications
Captopril, ≥98% (HPLC), powder
Captopril, United States Pharmacopeia (USP) Reference Standard
Captopril, European Pharmacopoeia (EP) Reference Standard
Captopril, Pharmaceutical Secondary Standard; Certified Reference Material
Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard